Pfizer

Pfizer is one of the largest pharmaceutical companies in the world, with a broad portfolio spanning vaccines, oncology, immunology and rare diseases. After the extraordinary revenue surge from its COVID vaccine and treatment, it has faced the challenge of replacing that income and rebuilding its pipeline, including through sizeable acquisitions in cancer therapy. Pfizer has paid dividends without interruption for four decades, and the yield sits well above the market average, a level that partly reflects investor caution about earnings after the pandemic bump faded. The payout is a priority for management, but its sustainability depends on stabilizing revenue and pipeline success. Its middling score captures a generous yield paired with genuine uncertainty over future growth.